Roche is wasting no time in getting out its checkbook in 2025, signing a new biobucks-heavy pact that aims to add another new antibody-drug conjugate (ADC) to its pipeline. Roche, which put ...

In separate DLL3 antibody-drug conjugate (ADC) deals, Roche licensed from Innovent Biologics and Ideaya reached for Hengrui. Experts weighed in on the potential implications and lessons from two ...

Rapt Therapeutics has charted a new course following the implosion of its lead program, agreeing to pay $35 million for a long-acting challenger to Novartis and Roche’s Xolair. A deal with ...

Attempt missed. Anthony Civet (La Roche-sur-Yon) right footed shot from the centre of the box is close, but misses to the left. Assisted by Mathieu Villette with a headed pass.

In amongst a clutch of discontinued phase 3 programmes in Roche's fourth-quarter results update was the news that it has stopped a study of AKT inhibitor ipatasertib as a treatment for first-line ...

Assisted by Kamory Doumbia. Attempt blocked. Matthieu Jacob (La Roche-sur-Yon) left footed shot from the right side of the box is blocked. Assisted by Alexis Araujo. Attempt blocked. Matthieu ...

FOXBORO – Hiring Mike Vrabel to be the next head coach of the New England Patriots was a no-brainer. Even if you take the events of 2024 out of the equation, Vrabel is still the right choice. He ...

MONTREAL, Jan. 8, 2025 /CNW/ - Fiera Capital Corporation (TSX: FSZ) ("Fiera Capital"), a leading independent asset management firm, is pleased to announce the promotion of Paul de la Roche to Head of ...

MONTREAL, Jan. 8, 2025 /CNW/ - Fiera Capital Corporation (TSX: FSZ) ("Fiera Capital"), a leading independent asset management firm, is pleased to announce the promotion of Paul de la Roche to Head ...

Those include Fibrogen's pamrevlumab and Roche's PRM-151 in phase 3 – as well as Novartis' ianalumab, Galecto Biotech's TD-139/, Bristol-Myers Squibb's CC-90001 and BMS-986278, and Liminal ...